Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 3/20 | 0.45 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.45 |
| ▸ | MKNK1 | Q9BUB5 | 4/20 | 0.44 |
| ▸ | CDK9 | P50750 | 7/20 | 0.44 |
| ▸ | CCNT1 | O60563 | 5/20 | 0.43 |
| ▸ | JAK3 | P52333 | 1/20 | 0.43 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.43 |
| ▸ | KIT | P10721 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 3/20 | 0.41 |
| ▸ | FLT1 | P17948 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5133445 | 0.90 | MKNK1 (0.48) | MKNK1CDK9CCNT1EGFR | |
| SCHEMBL5005721 | 0.90 | MKNK1 (0.46) | ROCK2ROCK1MKNK1CDK9CCNT1 | |
| SCHEMBL5001875 | 0.90 | CCNT1 (0.49) | ROCK2ROCK1MKNK1CDK9CCNT1 | |
| SCHEMBL14500369 | 0.88 | CDK9 (0.49) | ROCK2ROCK1CDK9CCNT1JAK3 | |
| SCHEMBL5004914 | 0.88 | MKNK1 (0.52) | ROCK2MKNK1EGFRFLT1 | |
| SCHEMBL13994107 | 0.87 | MKNK1 (0.48) | ROCK2MKNK1CDK9CCNT1CYP3A4 | |
| SCHEMBL5005801 | 0.86 | MKNK1 (0.52) | ROCK2MKNK1EGFRFLT1 | |
| SCHEMBL5130302 | 0.85 | MKNK1 (0.44) | ROCK2ROCK1MKNK1CDK9CCNT1 | |
| SCHEMBL5005834 | 0.85 | MKNK1 (0.51) | ROCK2MKNK1CDK9CCNT1EGFR | |
| SCHEMBL5008155 | 0.85 | ROCK2 (0.47) | ROCK2ROCK1MKNK1CDK9CCNT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150218173-A1 | SUBSTITUTED INDAZOL-PYRROLOPYRIMIDINES USEFUL IN THE TREATMENT OF HYPERFOLIFERATIVE DISORDERS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-08-06 | — | — | US | claimed |
| EP-2900670-A1 | SUBSTITUTED INDAZOL-PYRROLOPYRIMIDINES USEFUL IN THE TREATMENT OF HYPERFOLIFERATIVE DISORDERS | Bayer Pharma Aktiengesellschaft (DE) | 2015-08-05 | — | — | EP | claimed |
| US-20150218173-A1 | SUBSTITUTED INDAZOL-PYRROLOPYRIMIDINES USEFUL IN THE TREATMENT OF HYPERFOLIFERATIVE DISORDERS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-08-06 | — | — | US | disclosed |
| EP-2900670-A1 | SUBSTITUTED INDAZOL-PYRROLOPYRIMIDINES USEFUL IN THE TREATMENT OF HYPERFOLIFERATIVE DISORDERS | Bayer Pharma Aktiengesellschaft (DE) | 2015-08-05 | — | — | EP | disclosed |
| US-7465726-B2 | Substituted pyrrolo[2.3-B]pyridines | OSI PHARMACEUTICALS, INC. (US) | 2008-12-16 | — | — | US | disclosed |
| US-7465726-B2 | Substituted pyrrolo[2.3-B]pyridines | OSI PHARMACEUTICALS, INC. (US) | 2008-12-16 | — | — | US | disclosed |
| US-7465726-B2 | Substituted pyrrolo[2.3-B]pyridines | OSI PHARMACEUTICALS, INC. (US) | 2008-12-16 | — | — | US | disclosed |
| US-20060211678-A1 | Aryl-amino substituted pyrrolopyrimidine multi-kinase inhibiting compounds | OSI PHARMACEUTICALS, INC. | 2006-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211678-A1 | Aryl-amino substituted pyrrolopyrimidine multi-kinase inhibiting compounds | BMX, ERBB2, FRK | ROCK2 91/4885ROCK1 203/4885MKNK1 143/4885 |
| US-20150218173-A1 | SUBSTITUTED INDAZOL-PYRROLOPYRIMIDINES USEFUL IN THE TREATMENT OF HYPERFOLIFERATIVE DISORDERS | CCND2, ARG2, ARG1 | ROCK2 435/4885ROCK1 348/4885MKNK1 2957/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.